Vimarsana
Biggest News Aggregation in the World

Page 2 - Pharma Exec News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Exec. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Exec Today - Breaking & Trending Today

Former pharma exec, publicist charged with insider trading - Vimarsana News

Former pharma exec, publicist charged with insider trading

NEWARK, N.J. (AP) — A former executive and and a former communications director at a...

Former pharma exec, publicist charged with insider trading - Vimarsana News

Former pharma exec, publicist charged with insider trading

NEWARK, N.J. (AP) — A former executive and and a former communications director at a...

Source: ctpost.com
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China - Vimarsana News

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

/PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization...

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China - Vimarsana News

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

/PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization...

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China - Vimarsana News

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of